Trial Profile
An Open-label, Multicenter Protocol Providing Pegylated-interferon Alfa-2a (PEGASYS) as Monotherapy or in Combination With Ribavirin (COPEGUS) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols [Protocolo multicentrico abierto en el que se proporciona interferon pegilado alfa-2a (PEGASYS) en monoterapia o en combinacion con ribavirina (COPEGUS) a pacientes con hepatitis C cronica que han participado en protocolos de Roche anteriores]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Roche
- 01 Jun 2012 Status changed from recruiting to completed.as reported by ClinicalTrials.gov.
- 15 Jun 2010 Planned end date changed from 1 Jul 2015 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 17 Jul 2009 Actual initiation date (Apr 2009) added as reported by ClinicalTrials.gov.